SLC29A1 and myelodysplastic syndrome: measured the expression levels of hENT1 and hENT2 in 98 patients with MDS and found that patients responding to 5-AZA-dC displayed significantly higher hENT1 expression levels than non-responders, whereas hENT2 did not (83).